GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemCell Institute (TSE:7096) » Definitions » Net Current Asset Value

StemCell Institute (TSE:7096) Net Current Asset Value : 円112.49 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is StemCell Institute Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

StemCell Institute's net current asset value per share for the quarter that ended in Sep. 2024 was 円112.49.

The historical rank and industry rank for StemCell Institute's Net Current Asset Value or its related term are showing as below:

TSE:7096' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 10.44   Med: 23.8   Max: 34.85
Current: 10.58

During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of StemCell Institute was 34.85. The lowest was 10.44. And the median was 23.80.

TSE:7096's Price-to-Net-Current-Asset-Value is ranked worse than
78.29% of 981 companies
in the Biotechnology industry
Industry Median: 3.71 vs TSE:7096: 10.58

StemCell Institute Net Current Asset Value Historical Data

The historical data trend for StemCell Institute's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemCell Institute Net Current Asset Value Chart

StemCell Institute Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Current Asset Value
Get a 7-Day Free Trial 101.82 50.16 104.10 100.75 64.86

StemCell Institute Quarterly Data
Mar18 Mar19 Dec19 Mar20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.85 107.79 61.52 64.86 112.49

Competitive Comparison of StemCell Institute's Net Current Asset Value

For the Biotechnology subindustry, StemCell Institute's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemCell Institute's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemCell Institute's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where StemCell Institute's Price-to-Net-Current-Asset-Value falls into.


;
;

StemCell Institute Net Current Asset Value Calculation

StemCell Institute's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Mar. 2024 is calculated as

Net Current Asset Value Per Share(A: Mar. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(4515.04-3850.462-0-0)/10.247
=64.86

StemCell Institute's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2024 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(5217.421-4064.754-0-0)/10.247
=112.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemCell Institute  (TSE:7096) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


StemCell Institute Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of StemCell Institute's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


StemCell Institute Business Description

Traded in Other Exchanges
N/A
Address
Shimbashi, Minato-ku, Tamuracho Building, Matsuoka, Tokyo, JPN, 105-0004
StemCell Institute is engaged in Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's own cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood.

StemCell Institute Headlines

No Headlines